跳至主要内容
临床试验/NCT00646724
NCT00646724Unknown1 期

Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients

Fuzhou General Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2008年1月最近更新:
适应症

试验速览

阶段
1 期
入组人数
30
试验地点
1
主要终点
Exogenous insulin requirement

研究概览

简要总结

The study evaluates the safety and efficacy of Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients. The researchers hypothesize that additional Mesenchymal Stem Cell infusion can benefit the promising clinical islet transplantation through the following mechanisms: protection of islet from inflammatory damage, immunological modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin and improve β-cell function.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients age 18 to 60 years of age
  • Ability to provide written informed consent
  • Manifest signs and symptoms that are severe enough to be incapacitating
  • Patients with poor diabetes control (HbA1c > 7% but < 12%)
  • Progressive diabetic complications

排除标准

  • age < 18 years or > 60 years
  • diabetic history < 5 years
  • BMI > 27
  • body weight > 80 kg
  • exogenous insulin requirement > 1 unit/kg/day
  • severe anemia (male < 8 g/dl, female < 7 g/dl)
  • low white blood cell count (< 3000/dl)
  • liver dysfunction
  • Active infection including hepatitis B, hepatitis C, HIV, or TB
  • panel reactive antibody > 20%
  • Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial

结局指标

主要结局

Exogenous insulin requirement

时间窗: 5

Hemoglobin A1c

时间窗: 5

Glucose and C-peptide levels

时间窗: 5

次要结局

  • liver function(5)
  • kidney function(5)
  • Portal vein Ultrasound(1)
  • autoantibodies(5)
  • Complete Blood Count(5)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验